Key Points
- CEO August Troendle sold 2,410 Medpace shares at an average price of $620.07, generating approximately $1.49 million. His remaining stake totals 386,892 shares, representing a 0.62% reduction.
- Medpace reported quarterly EPS of $4.25, beating estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company’s FY 2026 EPS guidance is $17.25–$17.95.
- Analysts largely maintain a cautious view, with three Buy ratings and nine Holds; the consensus rating is Hold with an average price target of $595.20, below the stock’s $622.11 opening price.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 154 shares of the company's stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $620.60, for a total value of $95,572.40. Following the transaction, the chief executive officer directly owned 389,302 shares of the company's stock, valued at approximately $241,600,821.20. The trade was a 0.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Medpace Stock Up 1.0%
MEDP opened at $622.11 on Wednesday. The company has a market cap of $17.36 billion, a PE ratio of 36.47, a price-to-earnings-growth ratio of 2.75 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a 50-day moving average price of $598.22 and a 200 day moving average price of $518.32.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Institutional Investors Weigh In On Medpace
Several large investors have recently bought and sold shares of MEDP. Johnson Financial Group Inc. purchased a new position in shares of Medpace in the 2nd quarter valued at about $27,000. Jones Financial Companies Lllp purchased a new stake in shares of Medpace during the second quarter worth approximately $30,000. Allied Private Wealth LLC purchased a new stake in shares of Medpace during the second quarter worth approximately $31,000. Kilter Group LLC acquired a new stake in Medpace in the second quarter valued at approximately $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Medpace in the second quarter valued at approximately $34,000. Hedge funds and other institutional investors own 77.98% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on MEDP shares. Truist Financial increased their price target on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Mizuho increased their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $595.20.
Get Our Latest Report on Medpace
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
